

We are WHH



WHH Board of Directors Extra-Ordinary - Meeting Part 2

Wednesday 25 October 2017 10.45am-12.00pm Trust Conference Room



We are WHH



Warrington and Halton Hospital NHS Foundation Trust Agenda for a meeting of the Board of Directors held in public (Part 2)

Wednesday 25 October 2017, time 10.45am-12.00pm Trust Conference Room, Warrington Hospital

Warrington and Halton Hospitals NHS Foundation Trust. Agenda for a meeting of the Board of Directors Part 2 held in public. Wednesday 25th October 2017 10.45am-12.00pm Trust Conference Room, Warrington Hospital

AGENDA REF PBM/	ITEM	PRESENTER	PURPOSE	TIME	
BM/17/10/108	Welcome, Apologies & Declarations of Interest	Steve McGuirk, Chairman	N/A	10:45	Verbal
BM/17/10/109	Business Case for e- Prescribing	Jason DaCosta Director of IM+T	Approval		Paper
BM/17/10/110	Financial Position and Forecasting Year End	Andrea McGee Director of Finance + Commercial Development	Assurance	11.00am	РРТ
	Date of next meeting: 29 th November 2017, Trust Conference Room				



We are WHH

Warrington and Halton Hospitals NHS Foundation Trust

REPORT TO BOARD OF DIRECTORS

AGENDA REFERENCE:	BM/17/10/109	
SUBJECT:	ePrescribing (ePMA) B	Business Case
DATE OF MEETING:	25 October 2017	
ACTION REQUIRED	For approval	
AUTHOR(S):	Choose an item.	
EXECUTIVE DIRECTOR SPONSOR:	Jason DaCosta, Direc	tor of Information Technology
LINK TO STRATEGIC OBJECTIVES:	quartile in the North	all care is rated amongst the top West of England for patient mes and patient experience
LINK TO BOARD ASSURANCE FRAMEWORK (BAF):	BAF3.3: Clinical & Bu	siness Information Systems
	Choose an item.	
	Choose an item.	
STRATEGIC CONTEXT	Further develop the implementation of E	trust ePR through lectronic Prescribing.
EXECUTIVE SUMMARY (KEY ISSUES):	deploy Lorenzo ePresc increased patient safe	tunity to access central funding to ribing software. Benefits include ty and lower costs through reducing d forcing adherence to agreed
RECOMMENDATION:		isiness Case and the trusts through the NHS Digital centrally
PREVIOUSLY CONSIDERED BY:	Committee	Finance and Sustainability Committee
	Agenda Ref.	FSC/17/10/123
	Date of meeting	18 October 2017
	Summary of	To be recommended to the
	Outcome	board for consideration.
FREEDOM OF INFORMATION STATUS (FOIA):	Partial FOIA Exempt	
FOIA EXEMPTIONS APPLIED: (if relevant)	Section 43 – prejudic	ce to commercial interests



Date: 17th Oct 2017

BUSINESS CASE

Division: IM&T	Author:Jason DaCosta
	Executive Lead: Alex Crowe

Project: ePrescribing (ePMA)	
------------------------------	--

 Quality & Safety
 ✓
 Business Development
 ✓
 Capital

1.0 Purpose

This business case proposes to progress implementation of electronic prescribing and medicines administration (ePMA) deployment unit.

2.0 Background

In February 2016 Warrington & Halton Hospitals (WHH's) Executive Team took the difficult decision to reject a business case for electronic prescribing and medicines administration (ePMA) deployment unit - due to the need to stabilise the recently implemented Lorenzo deployment units. Concerns on speed and reliability of the system alongside the first of type implementer i.e. Sheffield University Hospitals NHSFT, had not approved a go-live date on their pilot ward.

There is a requirement by NHS Digital and as expected by the Care Quality Commission and NHS Improvement for the Trust to approve a viable plan to implement ePMA fully by 2020 which forms part of the approved Hospital Pharmacy Transformation Plan (HPTP).

This timescale is included in the Pharmacy Transformation Plan which went to board in May.

The Trust has been presented with a windows of opportunity to re-engage with DXC and NHS Digital to implement ePrescribing (known as ePMA by DXC) project through the funded Lorenzo programme. This window of opportunity closes in March 2018. Essentially, we need to be using live software by March 2018 to access funding though the NHS Digital agreement with DXC. Achieving a go live by March 2018 and therefore accessing this funding will save c£700k purchase and maintenance costs.

The addition deploying Lorenzo ePMA as our ePrescribing software will build on the investment in the single, shared digital ePR platform made to date and enable us to:

- Work towards achieving HiMSS level 7 ensuring patient safety and excellence in care and efficiency
- Make patient care safer through the use of ePMA that will reduce medication errors where prescribing is rules and evidence based.
- We ensure we have the right patient, give the right medication, and at the right time; and that prescribing, medications administration and compliance data is digitally captured and can be instantly shared





WHH's current system for prescribing and administration of medicines is paper based, with the exception of discharge prescriptions, ED and DVT clinic outpatient prescribing and chemotherapy. Problems with the current system include:

- 1. Illegible hand writing on prescriptions and charts
- 2. Transcription errors on prescription charts for new admissions, re-writes and discharges,
- 3. Recording of incomplete information on the prescribing order
- 4. In-appropriate prescribing orders,
- 5. Prescription of medication to which the patient is allergic or has had an adverse reaction to, or that interacts with other prescribed medication,
- 6. Lost or misplaced prescription charts,
- 7. Time wasted in transferring the prescription chart from wards to dispensary and back
- 8. Error in calculations for specific medicine doses,
- 9. CD record errors on administered controlled drugs,
- 10. Omitted doses when the prescription chart is off the ward,
- 11. Incorrect administration of the wrong drug, strength, dose or frequency of medication

EPMA systems are specifically designed to reduce the risks associated with traditional methods of prescribing and administering medicines highlighted above.

3.0 Proposed Service Development

The ePMA Deployment Unit comprising four parts:

Part 1 – initial prescribing and administration functionality

Part 2 – enhanced prescribing and administration functionality

Part 3 - dose range checking utilising FDB content

Part 4 – ward stock control

This project is to deploy Part 1 functionality **first go live** as a prototype to C21 Cardiology ward and CCU Coronary Care Unit 5th March 2018.

The business process covered:

- Medications Clerking
- Care on Ward
- Drug Rounds
- Discharge Transfer
- Pharmacist Verification and Dispense





4.0 Benefits

Reoccurring cash releasing benefits will start to be realised from 2019/20 . These cash releasing benefits have been calculated as follows:

Benefit Description	Rationale	Metric	Cash Releasing Value
Reduction in stationary costs	Based on 2016 / 17 expenditure on drug prescription kardexes	Annual cost of stopping paper prescirption items and purple pens.	£14,817
Improved medicines optimisation processes (source NHS Digital)	Improved adherence to the medicines formulary A key benefit will be tighter control of the antibiotics formulary with use of the correct antibiotic for the optimal period of time.	Drug Budget PBR tariff = £5m, assume 3% waste due to lack of adherence to formulary through using order sets.	£150,000
Reduction in misappropriation of medicines	Greater visibility of medicines usage in clinical areas	No baseline data	£10,000
Total Per annum			£174,817

Non cash releasing benefits from implementing an ePMA system have been estimated as follows:

Benefit Description	Rationale	Non-Cash Releasing Measure
Reduction in medication errors	Savings based on reductions in litigation (paid by insurance), reduced length of stay, and reduced costs of corrective treatments.	£888,641
Reduction in adverse drug reactions (ADRs)	Savings based on reduced admissions and bed occupancy	£100,000
Time saving on searching	Pharmacy staff	£10,000
for prescription charts/	Nursing staff	£69,437
misplaced charts	Medical staff	£35,000
Time saving on rewriting prescription charts	Medical staff time saved	£15,000
Time saving on transporting prescriptions to Pharmacy*	Electronic transmission of prescription / supply requests	£30,000
Total		1,148,078



Benefits	s Profil	e									
Cash releasing	g Savings										
Detail	15/16 £	16/17 £	17/18 £	18/19 £	19/20 £	20/21 £	21/22 £	22/23 £	23/24 £	24/26 £	All Years £
Cash Releasing Profile	0	0	0	0	87,409	174,817	174,817	174,817	174,817	174,817	961,494
Non Cash Rele	ease										
Detail	15/16 £	16/17 £	17/18 £	18/19 £	19/20 £	20/21 £	21/22 £	22/23 £	23/24 £	24/26 £	All Years £
Non Cash Releasing Profile	0	0	0	0	574,039	1,148,078	1,148,078	1,148,078	1,148,078	1,148,078	6,314,429
Total	0	0	0	0	661,448	1,322,895	1,322,895	1,322,895	1,322,895	1,322,895	7,275,923

The greatest benefits to be derived from implementing the EPMA system are those related to improving the safe provision of care to patients(See below)

- 1. Electronic access to GP records
- 3. Legible prescriptions, doses and frequencies, with no crossing out
- 5. Pre-populated order sets
- 7. Promotion of the Hospital Medicines Formulary
- Medicines database with alert functionality for drug – allergy and drug – drug interactions and patient – drug interactions
- 11. Information about medicines left unchanged, started, stopped and changed during admission are captured in the discharge prescription
- 13. Elimination of the use of inappropriate decimal points, abbreviations, unit measures.
- 15. More timely supply of medicines facilitated by electronic ordering on the ward and transmission to Pharmacy
- 17. Automated reports to provide accurate data highlighting issues with aspects of medicines management (e.g. non-formulary prescribing, noncompliance with Antibiotic Formulary, missed doses, duplicate orders) so that support can be provided to

- 2. Mandatory fields to capture allergies and sensitivities
- 4. Defined medication dose sentences
- Mandatory fields when generating an order set to ensure all minimum prescription data entered
- 8. Alert system for missed / late doses
- 10. Reduction in the need to transcribe on admission, no need to re-write prescriptions during the inpatient stay or transcribe at discharge
- 12. Ability to restrict prescribing access to certain drugs
- 14. Clear audit trail in terms of identifying prescriber, administrator, checker rather than determining illegible signatures
- Alert system to highlight 'critical medicines' to ensure timely administration
- Improved patient experience reduction in prescribing and administration errors, more timely supply of medicines (including critical medicines and medicines for discharge

Business Case





address the issues.

- 19. Electronic Patient Record better data quality and real time information
- 21. Eliminate rewriting of drug charts
- 23. Reduce duplication of work due to 'right first time'
- 25. Infection prevention and control promote antibiotic formulary compliance (e.g. indication and duration of treatment)
- 27. Administration alerts
- 29. Restricted access to certain antibiotics
- 31. Improved formulary compliance
- 33. Reputation demonstrating that we are a forward thinking organisation that utilises modern technology to improve care for patients

- 20. Improved work processes for staff eliminate searches for misplaced drug charts
- 22. Automated transcription of medicines into the discharge prescription
- 24. Automated transmission of medicine order from ward to dispensary
- 26. Alerts for at risk patients
- 28. Improved targeting of antibiotic ward rounds
- Cash releasing efficiencies no purchase of paper prescription charts
- 32. Reduced medicines misappropriation
- 34. Delivery of the EPMA element of the Digital roadmap

5.0 Financial Appraisal

Over the last 2 years The Trust has made substantial investment in ePR for both people and services. More specifically, an experienced Project team has been established for ePR Development and Benefits Realisation/Process Change. As a result the staff required to implement ePMA **first go live** in 17/18 will be utilising Trust resources, thereby negating the need for specialist expensive consultancy support

Service charges for Lorenzo and therefore ePMA for years 1 (15/16) to 6 (20/21) will be met by Department of Health and paid directly to DXC. The table below shows these charges transferring to the trust at 21/22.

The EPMA project will require a Programme Board which will report into the IM&T Board The Program Board would be supported by a Project Team, with flexible membership. A key role of the Board and Project Team will be to work with the wider clinical teams to promote full engagement with the process of EPMA roll-out and ensure successful implementation,

Narrative	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26	26/27	28/29	29/30	Total	
	£	£	£	£	£	£	£	£	£	£	£	£	£	
Capital Investment														
Purchase	0	250,000	250,000	0	0	0	0	0	0	0	0	0	500,000	
Revenue Investment														
BAU	267,000	0	0	0	0	0	0	0	0	0	0	0	267,000	
Maintenance	0	0	0	0	49,836	49,836	49,836	49,836	49,836	49,836	49,836	49,836	398,688	
Depreciation	0	25,000	50,000	50,000	50,000	50,000	50,000	50,000	50,000	50,000	50,000	25,000	500,000	
Interest	0	8,313	15,750	14,000	12,250	10,500	8,750	7,000	5,250	3,500	1,750	438	87,500	
	267,000	33,313	65,750	64,000	112,086	110,336	108,586	106,836	105,086	103,336	101,586	75,274	1,253,188	
Revenue Savings														
Cash Releasing	0	0	-87,409	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-1,660,762	
	0	0	-87,409	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-174,817	-1,660,762	
Net Revenue Impact (cash releasing only)	267,000	33,313	-21,659	-110,817	-62,731	-64,481	-66,231	-67,981	-69,731	-71,481	-73,231	-99,544	-407,574	
Revenue Savings														
Non Cash Releasing	0	0	-574,039	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-10,906,741	
	0	0	-574,039	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-1,148,078	-10,906,741	
Net Revenue Impact (cash and non releasing)	267,000	33,313	-595,698	-1.258.895	-1.210.809	-1,212,559	-1,214,309	-1.216.059	-1.217.809	-1.219.559	-1.221.309	-1.247.622	-11,314,315	

Assumptions

The prototype system is created in 17/18 using existing resources all ready employed. This BAU cost has been included as additional revenue investment in the table above.

Using existing staff will meet the 17/18 revenue investment costs.

Trust capital allocated for additional staffing to rollout the system across the remainder of the trust starting in 18/19 – namely one Programme Manager, one Product Specialist and one additional pharmacist (part time).

Additional training support will be provided if required from Trust BAU resources.

Final capital figures will be confirmed each year through capital programme allocation process and documentation.

No additional costs are required for estate and IT ward equipment or changes. Any changes or additions will be covered from BAU infrastructure programmes.


No provision for clinical backfill for training as the classroom training will be no more than 2 hours

24*7 support will be provided as is; wards will be expected to be self-sufficient. This will be reviewed after the first go-live of the prototype.

Half benefits start to be realised in year 5 (19/20); the full rollout will take 24 months from 18/19.

Capital asset life = 10 year









6.0 Risks

The table below represents the main risks that apply to ePMA first go live, at this time and will be managed by IMT Programme Board.

Risk No.	Risk/issue description	Impact score 1 = V Low 5 = V High	Likelihood score 1 = Rare 6 = Issue	Mitigating action plan/issue resolution plan	Estimated Cost of Risk £
001	Trust experiences operational problems when ePMA goes live	5	4	Continue to study the experiences of live Lorenzo sites carefully to ensure that our plans enable us to avoid the levels of disruption that some Trusts have experienced. However, in addition, maintain focus on support for staff affected by process changes and the introduction of new systems from the start of the project. Ensure that all staff have been fully trained in new procedures, are supported by written standard operating procedures in all cases, are clear about their individual new roles and adequate floor walkers/SMEs are in place before the system goes live. Ensure that the system has been fully tested and adequate performance levels have been demonstrated before go-live takes place. Ensure that the PID commitments of 80% of all users and 100% of all go-live staff, have been trained before go-live This should reduce the potential for operational problems at this point.	£20,00
006	Risk that as Lorenzo ePMA is a new DU it would be pragmatic to expect that critical fixes and/or product changes may be required.	3	3	Work with CSC product team from the early planning stages to ensure that product is fit for purpose for a day 1 go live, and ensure defects are fixed. Work closely with CSC and the Product Engagement group on future enhancements and product changes, for ePMA optimisation project.	£36,400

6.1 Failure Modes Effects Analysis (FMEA)

This will be completed as the rollout project commences and the final functionality and workflow of the system is known.





7.0 Recommendations

The recommendation is to approve the business case for the deployment of ePMA functionality, with 10 year costs to the trust of £1,253,188 and a cash release benefit of \pounds 1,660,762.

The system will become available as a prototype in C21 Cardiology ward and CCU Coronary Care Unit from the 5th March 2018. Final system configuration will be agreed in 18/19 as part of a trust wide rollout.

Amendment History

Issue	Date	Author	Reason
Version1	4/10/17	Sue Caisley	Originally described as a business development
Version2	6/10/17	Sue Caisley	Further input from IM&T demonstrated there was potential for this to be business case
Version 3	11/10/17	Alex Crowe & IM&T Board	Due to funding requirement from Trust it was deemed more of a business case that was not IT centric in order for Executive Team to be better placed to understand requirements. Detailed IMY Business Case supported as appendix
Final V1	16/10/17	Jason DaCosta & Diane Mathers	Final version following Finance and Pharmacy input in costs and benefits.
Final V2	17/10/17	Steve Barrow & Jason DaCosta	Update with 10 year financial profile.
Final V3	18/10/17	Jason DaCosta	Update following feedback at F&S and Executive Committee

						TB	WED Board 6			de		10.0	0 4.00			084							Onor	ational Com			lod)	
Г	Ne ar	re						-	-	as			10:00 - 4:00 SAME MONTH AS Q&A 9:00 - 12:00 ALTERNATIVE MONTH TO BOARD										QPS	ied)				
- I i						AC	THURS Audit				.												-					
	VV					Q&A	-		-	r NED	Chaired		2:00-5:00 SAME MONTH AS BOARD									KPI						
Ľ	-					NARC	WED NARC a	-	-				- 5:30			-				_			Work OPD EPRR					
Cor	'n	nato	Calend	lar v/	_	OB	MON Trust O	ps Boa	ard Mthly	Eds		1:00	- 5:00 2	DAYS BEFO	ORE BO	DARD (exce	ept wh	nere Bank	Holid	lay Mon	day)		STRAT					
	-					CFC	THURS Charit	able F	unds 1/4	y NEDs	5	1:30	-3:30										GOVE	RNORS CO	MMIT	TEES		
Ja	n :	2018	- Mar 2	2019		COG	THUR Council	of Go	overnors 1	/4ly NE	Ds CEO	4:00	- 6:00 1	st THURSD	AY Alt	ernate ven	ues W	/arrington	+ Ha	lton			QiC	TUES 11-1	Lpm 4	(yearly		
						FSC	WED Finance	+Susta	ainability N	/thly		2:00	-5:00 W	EDNESDAY	BEFOF	RE TRUST BO	OARD	1					GEG	WED 11-:	1pm 4	x yearl	у	
						вто	WED Board T	WED Board Time Out 4xyr NEDs/Eds A			ALL	DAY at H	IALTON								2019		2019		2019			
		Jan	Feb	Mar		Apr	May		June		July		Aug	Sep		Oct		Nov		Dec		Jan		Feb		Mar		
Mon	1	BH														1											Mon	
Tue	2						1 QIC/Q&A									2					1	BH					Tue	
Wed	3						2					1				3					2						Wed	
Thu	4		1	1			3					2				4	1				3						Thu	
Fri		OPD	2	2 OPD			4 OPD	1			OPD	3	\vdash	OPD		5	_	OPD	┝─┤	—	4		1		1		Fri	
Sat	6		3	3			5	2		⊢ ľ		4		1		6	3		1		5		2		2		Sat	
Sun	7		4	4	1		6	3		1		5		2	$\neg \vdash$	7	4		2		6		3		3		Sun	
Mon	/ 0	STRAT	5 STRAT	5 STRAT		BH	0 7 BH		STRAT	2		6	BH	3 STRAT		8 STRAT	_	STRAT	2		0 7		4		4		Mon	
Tue	0 9		6	6 Q&A	3		8 STRAT	4	JINAI		Q&A	7	ы			9		Q&A	3 4		8	010/02/1	4	┨	4	Q&A	Tue	
Wed	9 10	QIC/Q&A	7 GOVIND	7 Q&A	4		8 STRAT	6		4	CORA	8		4 <u>qic/q</u> &		9 LO	0 7	QCA	4 5		0 9	QIC/Q&A	6	┨	6	Clork	Wed	
Thu		Estate	8 Estate	8 Estate		Estate	10 Estate		Estate		Estate	<u> </u>		6 Estate		L1 Estate		Estate	6		10		7		7		Thu	
Fri		Flow	9 Flow	9 Flow	6		10 Estate		Flow			10		7 Flow		L2 Flow		Flow		Flow	10		8		8		Fri	
Sat	12	FIOW	10	10 10	7	riow	11 Flow	9	FIOW	7	low	11		8		L2 FIOW	10		8	FIOW	11		9		<u> </u>		Sat	
	13		10	10	8		12	10		8		11		9		L3 L4	10		。 9		12		10		10			
Sun			11 12	11			13	10		$ \rightarrow $		_		10			_		9 10				_		_		Sun	
Mon	15		12		9 10		14	11		9		13				15	12		10		14		11		11		Mon	
Tue	16			13				12		10		14		11		16	13				15		12		12		Tue	
Wed	17	GEG	14 15 CFC COG	14	11	GEG	16 17 ^{CFC} ^{COG}			11	GEG	15	CFCCOG	12			14 15		12 13		16		13	COG CFC	13		Wed	
Thu Fri	18 19	KDI	15 ^{CFC} ^{COG} 16 KPI	15 16 KPI	12 13 K	KDI	17 18 KPI	14 15	KDI	12 13	(PI	16 17		13 AMN 14		l8 l9 kpi	15		13	KDI	17 18	KDI	14 15		14		Thu Fri	
	20		10 KPT	16 KPT	14		19 NP1	16		14		18		15		20 KPT	17		15		19	KF1	16	KFI	16		Sat	
	21		18	18	15		20	17		15		19		16					16		<u> </u>						Sun	
Sun Mon	21	ICIC	10 19 ICIC	19 ICIC	16	ICIC			ICIC		ICIC	20		10 17 ICIC		21 22 ICIC	18	ICIC		ICIC	20 21		17		17 18		Mon	
		Work	20 Work		10	Nork	21 ICIC 22 WA	10	ICIC Work			20		17 ICIC 18 Work		23 Work		Work	17		21	Work	18	Work	18	Work-	Tue	
	23 24		20 Work 21 FSC	20 Work 21 FSC		FSC	22 WA 23 FSC			17	Nork FSC	21	FSC	18 Work 19 FSC				FSC			22	Work FSC	20	FSC	20		Wed	
	24 25		21 PSC 22 AC QPS	21 FSC 22 QPS		AC QPS		20	AC QPS		QPS	22		20 QPS		24 FSC 25 AC QPS			20	FSC		QPS		AC QPS			Thu	
		QP3			20	AC QPS	24 TB+End	21			2r5				┓╞	25 AC QPS 26				QP3		QPS	21	AC QPS			Fri	
	26		23	23						20		24		21			23		21		25		22		22			
	27		24	24 25	21		26 27	23 24		21 22		25		22		27	24		22		26		23		23		Sat	
Sun	28		25		22	0.0			0.0		0.0	26	DU	23		28	25		23		27	0.0	24		24		Sun	
Mon	29		26 OB	26 OB		OB	28 BH	25		23	OB	27	BH	24 OB		29 OB	26		24	D	28	OB	25	OB	25		Mon	
		EPRR	27 EPRR	27 EPRR	24 E		29 OB		EPRR		PRR	28	OB	25 EPRR		BO EPRR		EPRR	25		29		26	DEC	26		Tue	
	31	ТВ	28 BTO	28 TB	25	BLO	30 EPRR	27	BTO	25	ТВ	29		26 TB		B1 BTO	28		26	BH	30	ТВ	27	BTO	27		Wed	
Thu	┝──┤			29	26		31	28		26		30		27	┥┝		29		27		31		28		28		Thu	
Fri				30 BH	27			29		27		31		28			30		28						29		Fri	
Sat				31	28			30		28				29	\neg				29						30		Sat	
Sun					29					29				30	\downarrow				30						31		Sun	
Mon					30					30				31	$\exists L$				31		\mid						Mon	
Tue										31																	Tue	

School Hols 30 March-13 April 2018: 28 May-8 June 2018: Summer 23 July-1 September 2018: 22 October-26 October 2018: 21 December-2 January 2019: 18 February-22 February 2019 Easter 2019 5-23 April 2019